This article is part of a larger series on the risks of molnupiravir. For a summary of the risks at the level of the individual, see here, and for an overview of the risks on a societal level, see ...

Credit: Merck. The EUA was supported by data from the phase 3 MOVe-OUT trial, which compared the efficacy and safety of molnupiravir to placebo in 775 nonhospitalized adults with symptom onset within ...

In a recent study posted to the medRxiv* pre-print server, researchers evaluated the effectiveness of oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals, molnupiravir ...

This difference was driven by an increased benefit with placebo in the post–interim analysis phase, with a primary outcome event occurring in 20 of 324 participants who received molnupiravir and in 15 ...

The oral antiviral molnupiravir cuts the risk of hospitalization and death from COVID-19 by 50% in people who have mild to moderate forms of the disease. Merck & Co. and Ridgeback Biotherapeutics ...